WASHINGTON – November 17, 2021 – The Rare Disease Company Coalition, a unified voice of life science companies committed to discovering, developing and delivering rare disease treatments, welcomes the introduction of the bipartisan “Cures 2.0,” legislation by Representatives Diana DeGette (D-CO) and Fred Upton (R-MI) and encourages further engagement with Congressional leaders as it advances through the committee process.
“We applaud the continued leadership by Congresswoman DeGette and Congressman Upton to build on the success of the 21st Century Cures Act, and advance legislation that can better deliver modern treatments and cures to the countless Americans and rare disease patients that await options. As a diverse coalition representing life science companies dedicated to developing and delivering treatments for rare diseases, we look forward to continuing to work with Congressional stakeholders to provide feedback on the unique challenges and opportunities to unleash the promise of our R&D efforts aimed at tackling some of the most complex and devastating rare diseases,” said Betsy Ricketts, Chair of the Rare Disease Company Coalition. “
The Rare Disease Company Coalition represents life science companies committed to discovering, developing and delivering rare disease treatments for the patients we serve. As an education and advocacy-focused coalition of companies, our goal is to inform policymakers of the unique challenges and promises of rare disease drug discovery, development and manufacturing for small population sizes in order for critical innovation to continue. To achieve this goal, we will use our unified voice to advocate for long-term, consistent, equitable and sustainable government policies that enable life science companies to continue to bring hope and provide access to approved treatments to people living with rare diseases. For more information, please visit rarecoalition.com